The EDDC is a national platform for drug discovery and development to channel high potential drug candidates toward realising commercial outcomes for Singapore, as well as clinical outcomes that will benefit Singaporeans.
SINGAPORE (June 26): In an effort to give added momentum to Singapore’s drug development scene, two new national platforms and a grant scheme for drug and discovery development have been launched by the Agency for Science, Technology and Research (A*STAR).
These new initiatives will bridge the "valley of death" between basic science research and pharmaceutical enterprises; enhance collaboration across industry, research institutes, academia, and the hospitals; as well as nurture a strong pool of scientific talent for Singapore’s biomedical ecosystem, says A*STAR during the opening ceremony of the Experimental Drug Development Centre (EDDC) in Biopolis.
